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The National Cancer Institute and the National Institute for Diabetes and Digestive and Kidney 
Diseases initiated the Consortium for the study of Chronic Pancreatitis, Diabetes, and Pancreatic 
Cancer (CPDPC) in 2015 (the CPDPC’s origin, structure, governance and research objectives are 
described in another article in this journal). One of the key objectives of CPDPC is to assemble a 
cohort of 10,000 subjects ≥50 years with new-onset diabetes, called the NOD cohort. Using a DEF 
(Define, Enrich and Find) early detection approach, the aims of the NOD study are to: (a) estimate 
the 3-year probability of pancreatic ductal adenocarcinoma (PDAC) in NOD (Define); (b) 
establish a bio-bank of clinically annotated bio-specimens, from pre-symptomatic PDAC and 
control new-onset type 2 diabetes mellitus subjects; (c) conduct Phase 3 validation studies of 
promising biomarkers for identification of incident PDAC in NOD patients (Enrich); and (d) 
provide a platform for development of a future interventional screening protocol for early 
detection of PDAC in patients with NOD that incorporates imaging studies and/or clinical 
algorithms (Find). It is expected that 85-100 incidences of PDAC will be diagnosed during the 
study period in this cohort of 10,000 patients.
Keywords
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BACKGROUND AND SIGNIFICANCE
Among the most compelling needs to impact the dismal mortality associated with PDAC 
cases today is a rational, evidence-based strategy to detect the cancer at an early stage when 
it is still resectable, thereby permitting therapeutic options that result in long term survival. 
Greater than 90% of PDAC is sporadic (i.e. not arising in high risk cohorts of patients with 
an underlying germline mutation), and 85% of such sporadic PDAC patients present at an 
advanced stage, rapidly progressing to death.1 Some of the principal challenges to 
developing an early detection program for sporadic PDAC are the lack of an ascertainable 
high-risk group for sporadic PDAC; limited availability of high quality bio-specimens from 
pre-symptomatic cancer patients for study of biomarkers; a dearth of sensitive and specific 
biomarkers of early PDAC; and the inability of conventional imaging (and absence of novel 
imaging techniques) to identify early PDAC.1
A high-risk group for sporadic PDAC has been identified as subjects ≥50 years who have 
newly develop diabetes mellitus (NOD).2 Chari and colleagues first described in a 
retrospective population-based study of 2122 NOD subjects, 18 (0.85%) were diagnosed 
with PDAC within 3 years of meeting criteria for NOD,3 resulting in a 6-8-fold higher risk 
for PDAC than general population.3, 4 Small prospective screening studies for PDAC in 
NOD have also shown a 3-10% prevalence of PDAC in NOD.5-7 Conversely, ~25% of 
PDAC patients develop NOD between 6 and 24 months prior to cancer diagnosis.8 A recent 
study showed hyperglycemia precedes PDAC diagnosis by ~36 months, providing a possible 
window of opportunity for the early detection of pancreatic cancer in new-onset diabetes 
patients.9 The National Cancer Institute (NCI) has acknowledged that studying the 
relationship between DM and PDAC is one of the highest research priorities in PDAC 
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research.10 To respond to the challenges posed by early detection of sporadic PDAC, we 
developed the following research aims.
Specific Aims
We will prospectively develop a cohort of 10,000 subjects’ age ≥50 and ≤85 years with 
NOD to:
A. Estimate the probability of PDAC in the NOD Cohort,
B. Establish a biobank of clinically annotated bio-specimens including a reference 
set of bio-specimens from pre-symptomatic PDAC and controls new-onset type 2 
DM,
C. Conduct Phase 3 validation studies11 of promising biomarkers for identification 
of occult PDAC in NOD patients and,
D. Provide a platform for development of a future interventional screening protocol 
for early detection of PDAC in NOD patients that also incorporates imaging 
studies and clinical algorithms.
One key to accurately estimating the risk of harboring an occult PDAC in patients with NOD 
is to identify DM within a short time frame from first meeting biochemical criteria (defined 
as <90 days). In a pilot study at Mayo Clinic Rochester, investigators have been able to 
successfully identify incident DM subjects using surveillance of electronic databases and 
focused chart review (Examination of the Pancreas in New-onset Diabetes [EXPAND] trial; 
NCT0200133).
Rationale for NOD as a High-risk Group
The primary aim of NOD study is to estimate the incidence of PDAC in subjects with NOD. 
Based on previously published data, it is estimated that in the NOD cohort as defined, 
approximately 85 cases of incident PDAC will be diagnosed during the three years of study 
follow-up after meeting NOD study criteria, assuming the 1-year, 2-year, and 3-year 
cumulative incidence rate of PDAC is 0.63%, 0.73%, and 0.85%, respectively.12, 13 If 
diabetes in the study subjects is not due to a manifestation of occult PDAC, then the 
incidence rate of PDAC should be similar to the risk in the general population which is about 
0.04% per patient year. Conservatively, we use 0.1%, 0.2%, and 0.3% for 1-year, 2-year, and 
3-year cumulative risk, respectively, as null hypotheses. We will reject the null hypothesis of 
no association between NOD and PDAC if, one of the three observed proportions is 
significantly higher than the null hypothesis value, using an exact binomial test at a 2-sided 
nominal level 0.05/3. The power will be >90% to reject the null hypothesis if the true 1-year, 
2-year, and 3-year cumulative incidence rate is at least 0.43%, 0.64%, and 0.85%, 
respectively, i.e. 50%, 75%, and 100% of underlying PDACs will be clinically diagnosed 
during 1-year, 2-year, and 3-year since baseline.
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STUDY DESIGN SUMMARY
Assemble a Cohort of Subjects With NOD
A prospective cohort of 10,000 subjects will be enrolled with each subject participating for 
up to 3 years from the date they meet criteria for NOD (Table 1). A collaboration of CPDPC 
clinical centers, described in the CPDPC introductory paper in this journal and NCI 
Community Oncology Research Program (NCORP) sites will enroll subjects (Table 2).
Develop a Biobank Containing Longitudinal Samples From Subjects With NOD
All enrolled subjects will be passively followed for collection of clinical data and bio-
specimen samples at baseline (i.e., at the time of recruitment), and subsequently at 6, 12, and 
24 months (Figure 1). Blood (processed into aliquots of plasma, serum, buffy coat) stored 
will be stored for future studies.
Determine the Incidence of PDAC in a Prospective Cohort With NOD
The 1-year, 2-year, and 3-year incidence rates of PDAC during passive surveillance will be 
calculated using health records patient interviews.
Establish a Specimen Reference Set for High-risk Individuals
Future promising biomarkers for early detection of PDAC will be evaluated using this 
specimen reference set to calculate testing characteristics (sensitivity, specificity, positive 
predictive value [PPV], and negative predictive value [NPV]) for predicting 1-year, 2-year, 
and 3-year PDAC risk. These tests will then be useful clinically to stratify subsets of NOD 
that would benefit from early diagnostic work-up.
Develop a Platform for the Development of a Future Interventional Protocol for Early 
Detection of PDAC
Following development of predictive models and/or biomarkers of PDAC in NOD we will 
subsequently design a protocol to prospectively evaluate different screening protocols for 
PDAC in NOD patients.
DEFINITIONS AND ELIGIBILITY CRITERIA
Glycemic Definition of NOD
Parameters of DM (PDM) will be used to define the NOD state as described in Table 1. A 
strict biochemical definition of DM using American Diabetes Association (ADA) guidelines 
is being used to avoid delays that commonly occur in care teams formally making the 
diagnosis of diabetes.
Inclusion and Exclusion Criteria
An overview of inclusion and exclusion criteria is outlined in Table 3. The inclusion criteria 
will be used for invitation to the study. The study is designed to include women and 
minorities, but not to measure differences among them. No exclusion to this study will be 
based on race. Minorities will actively be recruited to participate.
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PDAC Definition
All PDAC cases will be defined as definite, probable and possible (Table 1). Only cases 
classified as definite or probable will be used for final analyses and biomarker discovery 
efforts.
SUBJECT ENROLLMENT PROCEDURES
The coordination and compliance activities of the NOD cohort will be managed by the 
NCI’s Early Detection and Research Network (EDRN) funded Data Management 
Coordination Center (DMCC), based in the Fred Hutchinson Cancer Research Center 
(Seattle, Wash). Subjects will provide written consent and HIPAA authorization prior to 
initiating study activities. All participating institutions will have access to a centralized data 
management using Validation Study Information Management System (VSIMS),14 a web-
based system designed by EDRN to automate the flow to maintain and quality control all 
data for: consent and HIPAA waiver, systematic review to confirm eligibility and other 
regulatory documents.
STUDY VISITS AND SPECIMEN COLLECTION
An overview of the activities is summarized below (Fig. 1):
Pre-screening/screening
Potential participants will be identified through searches of electronic medical records 
(EMRs), and/or through physician or self-referral. Once identified, the EMR will be 
reviewed to confirm NOD status and the patient will be invited to participate. Patients 
agreeing to participate will check-in to the approaching study site within 21 days of initial 
contact.
Baseline
Fasting (>8 hours) blood samples drawn for bio-banking and body weight will be obtained. 
For patients needing confirmation of NOD criteria, additional blood will be drawn for 
measuring fasting blood glucose (FBG) and glycosylated hemoglobin (HbA1c). If a patient 
meets NOD criteria on confirmatory testing, the participant and their primary care physician 
will be notified of the patient’s laboratory values and will be contacted to schedule the 6-
month follow-up visit.
Follow-up
Patients meeting NOD criteria at baseline will be asked to return for follow-up visits at 6, 
12, and 24 months. Follow-up questionnaires, blood (fasting), and body weights will be 
collected at each visit. If a subject misses a follow-up visit, the EMR will be reviewed to 
determine if they have developed interval PDAC.
End point follow-up (36 ± 2 months)
At 36-month follow-up, the subject will be contacted to determine if they have developed 
PDAC or other cancers. All subjects with PDAC will be invited to return to the study site for 
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a final blood draw (fasting) for biobanking. For subjects indicating no development of 
PDAC, their follow-up will be closed. The EMR will be reviewed for any subjects who are 
lost to follow-up for development of PDAC or other cancers.
Specimen Collection
At the baseline time point, 40 mL of blood will be drawn for patients with confirmed NOD 
criteria while those needing NOD confirmation, and additional 10mL of whole blood will be 
collected for measuring FBG and HbA1c (Fig. 1). For all patients, 40 mL of blood will be 
drawn at each subsequent follow-up visit. All patients with PDAC will be invited to return to 
the study site for a final blood draw. All blood specimens will be labeled and shipped to a 
central biorepository at NCI Frederick for long-term storage and use.
Criteria for Subject Removal From Study
A subject will be removed from study if: they develop PDAC or any other type of cancer 
(except basal cell carcinoma or in situ carcinoma of the cervix); completion of 3-year 
follow-up from the date they first met criteria for DM or the study ends; the patient 
withdraws from the study at any time for any reason; and medical or psychiatric illness 
which in the investigators judgement renders the subject incapable for further participation.
BIOMARKERS FOR EARLY DETECTION OF PDAC
Currently, there are no validated biomarkers for early PDAC due to lack of samples from 
pre-symptomatic PDAC patients. Therefore, a key aim of NOD study is to establish a 
biobank of clinically annotated bio-specimens in pre-symptomatic PDAC. To evaluate a 
future promising biomarker (or biomarker panel), we assume that the cutoff for the 
biomarker and the combination rule of the panel under evaluation has been pre-fixed in 
preliminary studies, so the NOD specimen reference set is used as a validation test set for its 
potential clinical utility of “rule-in” high risk patients for PDAC diagnostic workup (e.g. CT, 
MRI). Since the NOD population has high risk, PDAC is very lethal, and the workup is only 
moderately harmful in invasiveness and cost, the primary performance criteria should focus 
on high sensitivity for predicting 3-year risk of PDAC after baseline. The NOD study is 
designed to have the capacity to validate the sensitivity of a new biomarker in predicting 
PDAC within 1-year, 2-year, or 3-year after blood collection, since the lead time varies. 
Estimating development of 85 incident PDAC cases in this study, the half- length of 2-sided 
95% confidence interval for sensitivity ranges from 6.4% - 9.7% if the true sensitivity ranges 
from 90% - 70%.
The study sample size is primarily powered to study and validate a future biomarker as 
having a higher sensitivity compared to carbohydrate antigen (CA) 19-9, which is currently 
leading PDAC biomarker. CA 19-9 has not been evaluated in the NOD population for its 
sensitivity or specificity, but it is known that CA 19-9 has low sensitivity for PDAC at 
asymptomatic stage.15 We will assume 50% sensitivity for CA 19-9 on PDAC in NOD 
population. With 85 PDACs, the study will have at least 86% power if the sensitivity for the 
new test is at least 70%, assuming the new test and CA 19-9 is independent. However, they 
are likely to be positively correlated making the true study power to be greater than 90%. 
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The evaluation of specificity has ample power due to large number of controls. The half-
length of 95% confidence interval for specificity will be <1% if true specificity is at least 
50%.
With the 3-year cumulative incidence of 0.85%, the anticipated sensitivity >70% for a new 
test will have PPV of at least 2%, 2.9%, and 5.7%, if the specificity is at least 70%, 80%, 
and 90%, respectively, as compared to the background incidence rate 0.85%. This puts the 
yield of cancer in the test positive group compatible to that for colorectal cancer screening 
with fecal occult-blood tests for people aged >50 (PPV, 2.5-5.0%; sensitivity, 69-79%),16 or 
that for lung cancer LDCT screening for heavy smokers (PPV, 3.6%).17 Therefore, this NOD 
cohort is powered to validate a new test with clinical useful performance as a second sieve 
for PDAC early detection following the identification of NOD as the first sieve.
Developing an effective strategy for early detection of finding PDAC is essential to result in 
improvements in survival. Diagnosis of pre-symptomatic PDAC is anticipated to result in a 
cancer stage shift that would allow patients access to potential cures or delayed disease 
progression. The NOD study will provide key results that will advance the field of early 
detection of PDAC through accurately describing the incidence of PDAC in this high-risk 
population, defining subsets of NOD at highest risk, and providing a platform for validation 
of promising, early, diagnostic biomarkers.
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FIGURE 1. 
Overview of activities of the new-onset diabetes study.
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TABLE 1.
Study Definitions and Criteria Used in the NOD Study
Terms Study Definitions
Glycemic Parameters Only the following glycemic parameters measured in outpatient setting are to be assessed:
  • Fasting blood glucose (FBG)
  • Random (non-fasting) glucose
  • Glycosylated hemoglobin (HbA1c)
  • 2h blood glucose following 75 gm glucose load (oral glucose tolerance test [OGTT])
The following glucose measurements are not included: urine glucose, other body fluid glucose, blood glucose 
measured in emergency department, urgent care, or inpatient setting
Parameters of Diabetes 
Mellitus (PDM)
  • Fasting blood glucose (≥126 mg/dl)
  • Random blood glucose (≥200 mg/dl)
  • Glycosylated hemoglobin (HbA1c) (≥6.5%)
  • 2h post oral glucose load (PG) ≥200 mg/dl during OGTT
Diagnosis of Diabetes 
(DxDM)
Any (1) of the following:
  • Any (2) PDMs present on consecutive or simultaneous testing
  • On anti-diabetic medications preceded by at least (1) PDM*
Date of meeting criteria 
for DM (DtDM)
Whichever of the following is earliest:
  • Date of first of (2) consecutive or simultaneous measured PDMs
  • Date of first PDM if patient is started on anti-DM medications following this measurement
New-onset DM Meets all the following criteria:
  • Age ≥50 and ≤85 years
  • Date of meeting criteria for DM ≤90 days prior to enrollment
  • Have had glycemic parameter(s) measured in the 3-18 months prior to screening (demonstrating absence 
of PDM)
PDAC Definition
  • Definite: Requires biopsy proof of pancreatic adenocarcinoma on autopsy, biopsy, or surgical resection of 
pancreatic lesion or adenocarcinoma on biopsy of a metastatic lesion with imaging evidence of pancreatic mass
  • Probable: presence of one of the following: 1. Obstructive jaundice and low-density pancreatic head 
mass, OR 2. Low density pancreatic mass and elevated serum CA 19-9 level
  • Possible: Jaundice, anorexia, and/or weight loss associated with an indeterminate pancreatic lesion or 
normal pancreatic imaging
*
If patient has (1) PDM and has started anti-diabetic medication within 3 months; repeat value may or may not meet PDM, patient is still eligible.
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TABLE 2.
Study Sites Participating in NOD Study
Site/Group Site Name
Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer 
(CPDPC) Clinical Centers
Baylor College of Medicine
Cedars-Sinai Medical Center
Mayo Clinic, Minnesota
The Ohio State University Wexner Medical Center
University of Florida
University of Pittsburgh Medical Center
Indiana University, Indianapolis
Stanford University Medical Center
NCI Community Oncology Research Program (NCORP) St. Joseph Mercy Health System
Kaiser Permanente Northern California
Multicare Health System
Other Kaiser Permanente Southern California
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TABLE 3.
Overview of Eligibility Criteria for New-Onset Diabetes (NOD) Study
Category Inclusion criteria Exclusion criteria
Age Consent Willing to provide and sign informed consent form 
≥50 and ≤85 years
DM-related • Must have at least (1) PDM in past 90 days 
measured in outpatient setting:
 • FBG≥126mg/dl;HbA1c≥6.5%; RBG≥200mg/dl; 
2h post-glucose≥200mg/dl(OGTT)
• Must have had glycemic parameter measured in 
3-18 months prior to screening without meeting DM 
criteria
• Must not be on anti-DM medications prior to 
meeting study entry criteria
• patient met criteria for DM>90 days prior to 
enrollment, carried a physician DM diagnosis or 
used anti-DM medications in 3-18 months prior to 
enrollment
• Has had no glycemic parameter measured 
within 3-18 months prior to enrollment
Bio-specimen/Questionnaire Patient must be willing to provide blood sample 
(fasted) at baseline and complete a detailed 
questionnaire
For subsequent serial bio-sampling patient must meet 
criteria for NOD (Table 1) and willing to provide 
blood samples/complete questionnaires (Figure 1)
Personal history of cancer Should not have a prior history of pancreatic cancer
No history of other active cancers (excluding basal cell 
carcinoma or carcinoma in situ of cervix)
Must not be on active cancer treatment, carry a 
current cancer diagnosis, and/or be investigated 
for suspicion of past cancer recurrence
Any past history of pancreatic cancer
Steroid use or acute illness 
blood draw
Current chronic or acute oral steroid
Recent (<1 week) intra-articular steroid injections 
(allowed: nasal, topical, oral budesonide)
Blood sugar measured in urgent care, emergency 
visit, or as inpatient
Chronic severe illness In physician’s judgement patients co-morbidities do 
not limit patient’s participation in study interventions
Patients must not have any significant medical 
illness that in the investigator’s opinion cannot be 
adequately controlled with appropriate therapy or 
would compromise the patient’s ability to tolerate 
study interventions.
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